Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00940225 · OUTCOME

Overall Survival (OS) - NRE Cohorts, CRPC and Ovarian Only

Study of Cabozantinib (XL184) in Adults With Advanced Malignancies · Source last updated 2024-04-25

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
95% Confidence Interval
Time frame
From initial dose through final study visit up to 15 months

Groups in this outcome

NRE Cohort - CRPC 100 mg

cabozantinib, 100 milligrams orally, daily for 12 weeks until progression or unacceptable toxicity.

NRE Cohort - CRPC 39.4 mg

cabozantinib, 39.4 milligrams orally, daily for 12 weeks until progression or unacceptable toxicity.

NRE Cohort - Ovarian 100 mg

cabozantinib, 100 milligrams orally, daily for 12 weeks until progression or unacceptable toxicity.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
NRE Cohort - CRPC 100 mg93
NRE Cohort - CRPC 39.4 mg51
NRE Cohort - Ovarian 100 mg60

Reported measurements

Source class 1
Values in months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
NRE Cohort - CRPC 100 mg11.1Not reported9.1713.34Not reported
NRE Cohort - CRPC 39.4 mg8.0Not reported7.92NAUnable to Estimate due to low numbers.
NRE Cohort - Ovarian 100 mg8.5Not reported5.8811.73Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        9.17
        upper Limit
        13.34
        value
        11.1
      2. comment
        Unable to Estimate due to low numbers.
        group Id
        OG001
        lower Limit
        7.92
        upper Limit
        NA
        value
        8.0
      3. group Id
        OG002
        lower Limit
        5.88
        upper Limit
        11.73
        value
        8.5
denoms
  1. counts
    1. group Id
      OG000
      value
      93
    2. group Id
      OG001
      value
      51
    3. group Id
      OG002
      value
      60
    units
    Participants
dispersion Type
95% Confidence Interval
groups
  1. description
    cabozantinib, 100 milligrams orally, daily for 12 weeks until progression or unacceptable toxicity.
    id
    OG000
    title
    NRE Cohort - CRPC 100 mg
  2. description
    cabozantinib, 39.4 milligrams orally, daily for 12 weeks until progression or unacceptable toxicity.
    id
    OG001
    title
    NRE Cohort - CRPC 39.4 mg
  3. description
    cabozantinib, 100 milligrams orally, daily for 12 weeks until progression or unacceptable toxicity.
    id
    OG002
    title
    NRE Cohort - Ovarian 100 mg
param Type
MEDIAN
reporting Status
POSTED
time Frame
From initial dose through final study visit up to 15 months
title
Overall Survival (OS) - NRE Cohorts, CRPC and Ovarian Only
type
SECONDARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice